Compare SRCE & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SRCE | DFTX |
|---|---|---|
| Founded | 1863 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1995 | N/A |
| Metric | SRCE | DFTX |
|---|---|---|
| Price | $73.62 | $22.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $74.50 | $38.50 |
| AVG Volume (30 Days) | 120.0K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $44.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.89 | $14.62 |
| 52 Week High | $76.44 | $26.25 |
| Indicator | SRCE | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 56.44 |
| Support Level | $65.26 | $16.37 |
| Resistance Level | $75.80 | $26.25 |
| Average True Range (ATR) | 1.86 | 1.46 |
| MACD | -0.23 | -0.22 |
| Stochastic Oscillator | 35.08 | 31.27 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).